Kamada (NASDAQ:KMDA – Get Free Report) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.11 by $0.05, FiscalAI reports. Kamada had a net margin of 11.21% and a return on equity of 7.73%. The business had revenue of $54.92 million during the quarter, compared to analyst estimates of $50.84 million.
Here are the key takeaways from Kamada’s conference call:
- Record first-half performance: Revenue rose 13% year over year to $100.2 million, adjusted EBITDA increased 14% to $25.7 million, and net income grew 18% to $13.4 million. Second-quarter revenue and EBITDA also reached company records, with a 26% EBITDA margin.
- Kamada reiterated its 2026 guidance of $200 million–$205 million in revenue and $50 million–$53 million in adjusted EBITDA, noting that first-half results are approximately 50% of the annual midpoint and that it remains comfortable with second-half expectations.
- The company signed a three-year, $50 million normal-source plasma supply agreement, with initial commercial sales expected in the fourth quarter of 2026. Houston and San Antonio facilities are expected to provide roughly $16 million–$20 million of annual capacity, while specialty plasma will support Kamada’s own products.
- Management reported continued demand growth for KEDRAB, VARIZIG, HepaGam B and other commercial products, alongside expansion of its biosimilar distribution business in Israel and the MENA region. Kamada expects its biosimilar portfolio to generate $15 million–$20 million in annual sales within several years.
- CFO Chaime Orlev will leave the company at the end of 2026 after nine years, and Kamada has begun searching for a successor, creating a near-term executive-transition risk.
Kamada Price Performance
Kamada stock traded down $0.22 during mid-day trading on Wednesday, reaching $6.87. The stock had a trading volume of 335,841 shares, compared to its average volume of 60,547. The company has a market capitalization of $395.09 million, a price-to-earnings ratio of 19.63, a PEG ratio of 0.65 and a beta of 0.86. Kamada has a one year low of $6.50 and a one year high of $9.35. The company has a 50-day moving average price of $7.23 and a two-hundred day moving average price of $7.98.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on KMDA
Hedge Funds Weigh In On Kamada
Several hedge funds and other institutional investors have recently added to or reduced their stakes in KMDA. Barclays PLC increased its holdings in shares of Kamada by 417.1% in the 4th quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 3,862 shares in the last quarter. XTX Topco Ltd bought a new stake in Kamada in the 4th quarter worth about $103,000. SIH Partners LLLP bought a new position in Kamada during the 4th quarter valued at about $134,000. Quadrature Capital Ltd boosted its holdings in shares of Kamada by 53.5% during the 4th quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock valued at $155,000 after acquiring an additional 7,627 shares during the last quarter. Finally, Jump Financial LLC purchased a new stake in shares of Kamada during the 2nd quarter valued at about $219,000. 20.38% of the stock is owned by institutional investors.
Kamada News Summary
Here are the key news stories impacting Kamada this week:
- Positive Sentiment: Quarterly results exceeded expectations. Kamada reported adjusted EPS of $0.16, above the $0.11 consensus estimate, while revenue of $54.92 million surpassed expectations of $50.84 million. The company also reported an 11.21% net margin and 7.73% return on equity. Kamada quarterly earnings results
- Positive Sentiment: Record performance and maintained outlook. Kamada described the second quarter and first half as the strongest in its history, citing double-digit profitable growth. Management affirmed 2026 annual guidance, including revenue of approximately $200 million to $205 million. Kamada reports second-quarter and first-half 2026 results
- Neutral Sentiment: Investors received additional operating detail on the earnings call. The call transcript discusses quarterly results, product performance, and the company’s outlook, which may help investors assess whether the growth is sustainable. Kamada Q2 2026 earnings call transcript
- Negative Sentiment: CFO transition creates an execution risk. Chief Financial Officer Chaime Orlev will leave effective December 31, 2026, after serving in the role since 2017. Kamada has begun searching for a successor, although Orlev is expected to assist with the transition. Kamada announces CFO transition
Kamada Company Profile
Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.
Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.
Featured Stories
- Five stocks we like better than Kamada
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
- Intel’s Rally Gave It a $20 Billion Opportunity and Now Comes the Hard Part
- Visa’s AI Opportunity Is Hiding in Every Transaction
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.
